- Home
- Equipment
- north america
- cancerous target
Show results for
Refine by
Cancerous Target Equipment Supplied In North America
102 equipment items found
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food and Drug Administration (FDA) to test TVI-Brain-1 in a Phase 2b clinical study for glioblastoma multiforme (GBM). The Fast Track Designation is supported by positive ...
Manufactured by:Reglagene Holding, Inc. based inTucson, ARIZONA (USA)
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...
Manufactured by:Lightpoint Medical, Ltd based inWaterside, UNITED KINGDOM
SENSEI is an advanced guidance system for minimally-invasive and robot-assisted surgical procedures, offering unprecedented intracavity maneuverability and anatomic ...
Manufactured by:Lightpoint Medical, Ltd based inWaterside, UNITED KINGDOM
An advanced guidance system designed for intracavity radio-guided surgery. The miniaturized SENSEI® probe enables unprecendented dexterity and anatomic reach, expanding the field of view and enabling the quick localization of radioactive hotspots. Suitable for minimally-invasive and robot-assisted surgical ...
Manufactured by:Lightpoint Medical, Ltd based inWaterside, UNITED KINGDOM
SENSEI is an advanced guidance system for minimally-invasive cancer surgery, offering unprecedented intracavity maneuverability and anatomic ...
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
Premium
Manufactured by:Vobis LLC based inEaston, PENNSYLVANIA (USA)
We have developed proprietary lipid based nano technologies that have potential benefits in different therapeutic areas including targeted cancer therapy, DNA Vaccination and liver diseases. Here are the some of the highlights related to our LNP and liposomal experience including type of liposomes and techniques. ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of care. With uncertainty in how to interpret PSA test results, ...
Manufactured by:ALL Chemistry Inc. based inMarlton, NEW JERSEY (USA)
TJ191 is a selective anti-cancer agent, targeting low TβRIII-expressing malignant T-cell leukemia/lymphoma ...
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient's immune system for optimized antigen presentation, and engaging both cellular and humoral ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
This advanced functional class is referred to as Heterogeneity overcoming - Immunogenic death inducing - Resistance antagonizing - Enhanced Specificity (HIRE) molecules that target cancer cells. While HIRE molecules provide cancer cells specific targeting, and exert bi-modal proliferative inhibition, any cancer ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based cancer therapeutics that target tumors expressing mHsp70, and other (undisclosed) targets. Gene editing of allogeneic CAR NK cells will ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Our first multi-targeted Treatment System is comprised of VOR33-CLL1 multiplex-edited eHSC therapy and VCAR33-CLL1 multi-specific CAR-T therapy. Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional class is ...
Manufactured by:SystImmune Inc. based inRedmond, WASHINGTON (USA)
Antibody Drug Conjugates (ADC) molecules utilize specific antibodies to deliver therapeutic small molecules specifically to cancer cells. ADC are created in cooperation with Bai-Li Pharmaceutical’s R&D Center of Excellence and enable the development of sophisticated chemistries that give this class of drugs their therapeutic payload. This advanced functional ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
APH-0912 is a combination of a Taxotere® prodrug and monoclonal antibody targeted to treat metastatic cancer. The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After ...